This clinical trial is for women with metastatic breast cancer. There is currently a need for more effective treatment methods for this disease.
The study drug that is being investigated in this clinical trial, SGN-LIV1A, is a type of drug called an antibody drug conjugate (ADC). This study is being done to find out what side effects are caused in patients with breast cancer who are given SGN-LIV1A (single therapy) and SGN-LIV1A in combination with trastuzumab (combination therapy).
This study will be conducted in 3 parts:
- Part A (single therapy) with SGN LIV1A
- Part B (combination therapy) with SGN-L1V1A and trastuzumab
- Part C (single therapy) with a defined dose regimen of SGN LIV1A given to patients with triple negative breast cancer
You will be given SGN-LIV1A or SGN-LIV1A in combination with trastuzumab treatment in 21-day cycles. If your cancer is stable or gets better with SGN-LIV1A or the combination therapy, you may continue to be treated in the study.
Following the end-of-treatment tests, you will have follow-up visits and/or follow-up phone calls every 12 weeks for the first year and then every 24 weeks until the study has been completed.